featured
Umbralisib in Patients With Relapsed or Refractory Indolent Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
J. Clin. Oncol 2021 Mar 08;[EPub Ahead of Print], NH Fowler, F Samaniego, W Jurczak, N Ghosh, E Derenzini, JA Reeves, W Knopińska-Posłuszny, CY Cheah, T Phillips, E Lech-Maranda, BD Cheson, PF Caimi, S Grosicki, LA Leslie, JC Chavez, G Fonseca, S Babu, DJ Hodson, SH Shao, JM Burke, JP Sharman, JY Law, JM Pagel, HP Miskin, P Sportelli, OA O'Connor, MS Weiss, PL ZinzaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.